Evidence map›Paper›PMID 38894648›Full record

ArticleBrain and behavior2024

Modulation of habenular and nucleus accumbens functional connectivity by ketamine in major depression.

Brandon Taraku, Joana R Loureiro, Ashish K Sahib, Artemis Zavaliangos-Petropulu, Noor Al-Sharif, Amber M Leaver, Benjamin Wade, Shantanu Joshi, Roger P Woods, Randall Espinoza and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Brandon TarakuAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-7998-1128
Joana R LoureiroAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Ashish K SahibAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Artemis Zavaliangos-PetropuluAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Noor Al-SharifAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Amber M LeaverDepartment of Radiology, Northwestern University, Chicago, Illinois, USA.
Benjamin WadeDivision of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-2461-6101
Shantanu JoshiAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Roger P WoodsAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
Randall EspinozaDepartment of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California, USA.
Katherine L NarrAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.

Funding

UCLA Medical Genetics Training ProgramT32GM008243 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Julian Martinez-Agosto, STANLEY F. NELSON · 1987 to 2026
$6.8M
Perturbation of the treatment resistant depression connectome by fast-acting therapiesU01MH110008 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ESPINOZA, RANDALL, NARR, KATHERINE L · 2016 to 2019
$5.5M
Biomarkers of fast acting therapies in major depressionK24MH102743 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NARR, KATHERINE L · 2014 to 2018
$889k
NIGMS NIH HHS T32 GM008243NIMH NIH HHS K24 MH102743NIMH NIH HHS MH102743NIMH NIH HHS MH110008NIMH NIH HHS U01 MH110008
6 · The paper itself

Abstract

introductionMajor depressive disorder (MDD) is associated with dysfunctional reward processing, which involves functional circuitry of the habenula (Hb) and nucleus accumbens (NAc). Since ketamine elicits rapid antidepressant and antianhedonic effects in MDD, this study sought to investigate how serial ketamine infusion (SKI) treatment modulates static and dynamic functional connectivity (FC) in Hb and NAc functional networks.

methodsMDD participants (n = 58, mean age = 40.7 years, female = 28) received four ketamine infusions (0.5 mg/kg) 2-3 times weekly. Resting-state functional magnetic resonance imaging (fMRI) scans and clinical assessments were collected at baseline and 24 h post-SKI. Static FC (sFC) and dynamic FC variability (dFCv) were calculated from left and right Hb and NAc seeds to all other brain regions. Changes in FC pre-to-post SKI, and correlations with changes with mood and anhedonia were examined. Comparisons of FC between patients and healthy controls (HC) at baseline (n = 55, mean age = 32.6, female = 31), and between HC assessed twice (n = 16) were conducted as follow-up analyses.

resultsFollowing SKI, significant increases in left Hb-bilateral visual cortex FC, decreases in left Hb-left inferior parietal cortex FC, and decreases in left NAc-right cerebellum FC occurred. Decreased dFCv between left Hb and right precuneus and visual cortex, and decreased dFCv between right NAc and right visual cortex both significantly correlated with improvements in mood ratings. Decreased FC between left Hb and bilateral visual/parietal cortices as well as increased FC between left NAc and right visual/parietal cortices both significantly correlated with improvements in anhedonia. No differences were observed between HC at baseline or over time.

conclusionSubanesthetic ketamine modulates functional pathways linking the Hb and NAc with visual, parietal, and cerebellar regions in MDD. Overlapping effects between Hb and NAc functional systems were associated with ketamine's therapeutic response.

Indexed as

HabenulaKetamineMagnetic Resonance ImagingMajor Depressive DisorderNucleus AccumbensAdultAnhedoniaAntidepressive AgentsFemaleHumansMaleMiddle AgedAntidepressive AgentsKetaminefMRIhabenulaketaminenucleus accumbensreward

Identifiers

PMID38894648
PMCPMC11187958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.